Our extensive experience in health technology assessment (HTA) through providing strategic advice and guiding evidence generation to support submissions to UK HTA bodies, enables us to provide you with a tailored solution to reimbursement and patient access.
Welcome to Our insights
We keep informed with up-to-the-minute HTA news to provide bespoke advice with a local and global strategy for market access. We share our strategic thoughts on the latest industry insights, and how we can partner you to navigate the HTA process and plan for success.
Publications
Economic Evidence for Envarsus® Kidney Transplant Recipients: A Targeted Literature Review to Support UK Cost-Effectiveness Modelling. Presented at: ISPOR Europe 2026; 9-11 November 2026; Vienna, Austria.
Trends in Utility Values Applied in National Institute for Health and Care Excellence (NICE) Technology Appraisals for Non-Small Cell Lung Cancer (NSCLC). Presented at: ISPOR Europe 2026; 9-11 November 2026; Vienna, Austria.
A Framework Approach to Assess the Evidence Generation Needs for Two Novel Treatments in Sickle Cell Disease Preparing for UK Health Technology Assessment: A Case Study. Presented at: ISPOR Europe 2026; 9-11 November 2026; Vienna, Austria.
Real-World Comparator Evidence for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: Derivation of an NHS England Registry Cohort to Support Indirect Comparative Effectiveness Analyses. Presented at: ISPOR Europe 2026; 9-11 November 2026; Vienna, Austria.
EQ-5D-5L-derived utility drivers of HRQoL in HAE and comparison with patient-reported qualitative findings. Presented at: ISPOR Europe 2026; 9-11 November 2026; Vienna, Austria.
Evaluating AI versus Human-Led Inductive Thematic Analysis of Patient Interviews: A Case Study in Treatment Preferences for Non-Muscle-Invasive Bladder Cancer. Presented at: ISPOR Europe 2026; 9-11 November 2026; Vienna, Austria.
From Early Access to Routine Reimbursement: How Does the SMC Ultra-Orphan Pathway Address Evidence Gaps to Support Reimbursement Decisions? Presented at: WODC Europe 2026; 27-28 October 2026; Amsterdam, Netherlands.
Cost-Effectiveness of Once Weekly Rezafungin for theTreatment of Invasive Candidiasis in the United Kingdom
The 2023 EB Insights Study: the impact of epidermolysis bullosa on carer health-related quality of life. Poster PCR226. Presented at: ISPOR Europe 2025; 10-12 November 2025; Glasgow, UK.
A systematic approach to understanding challenges in the health technology assessment of rare diseases. Presented at: WODC Europe 2025; 28-29 October 2025; Amsterdam, Netherlands.
A New Process Model of Study Identification Specific to the Identification of Randomised Studies for Systematic Reviews of Medical Interventions
Cost‑Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective
A New Process Model for Study Identification in Systematic Review: Separating Studies From Reports. Poster SA80. Presented at: ISPOR Europe 2024; 17-20 November 2024; Barcelona, Spain.
Health technology appraisals of gene therapies appraised through NICE
highly specialised technology route. Poster HTA35. Presented at: ISPOR Europe 2024; 17-20 November 2024; Barcelona, Spain.
SLRs could benefit from a new approach to study identification: a case study. Poster SA105. Presented at: ISPOR Europe 2024; 17-20 November 2024; Barcelona, Spain.
What’s my age again? Exploring the importance of patient age assumptions
in calculating severity modifiers. Poster HTA406. Presented at: ISPOR Europe 2024; 17-20 November 2024; Barcelona, Spain.
Challenges in identifying information to build economic evaluations in hereditary angioedema. Poster EE754. Presented at: ISPOR Europe 2024; 17-20 November 2024; Barcelona, Spain.
The 2023 EB Insights Study: the impact of epidermolysis bullosa on the health related quality of life of patients and their carers. Poster PCR97. Presented at: ISPOR Europe 2024; 17-20 November 2024; Barcelona, Spain.
What are health utilities? Hayward Medical Publishing (2009).
Exploring the impact of excessive daytime sleepiness caused by obstructive sleep apnea on patient and partner quality of life: a time trade-off utility study in the UK general public. J Clin Sleep Med. 2022;18(9):2237–2246.
A systematic review of clinical efficacy and safety data in penta-refractory multiple myeloma: findings indicate the challenges for HTA submission. Poster HTA236. Presented at: ISPOR Europe 2023; 12-15 November 2023; Copenhagen, Denmark.
A structured expert elicitation exercise conducted with UK clinicians to inform and validate inputs for a cost-effectiveness analysis of Filsuvez® gel (birch bark extract) in epidermolysis bullosa. Poster CO106. Presented at: ISPOR Europe 2023; 12-15 November 2023; Copenhagen, Denmark.
Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review. The European Journal of Health Economics (2023) 24:453–467.